Artificial Intelligence In Precision Medicine Market, 2028- Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028 Segmented By Technology (Deep Learning, Querying Method, Natural Language Processing, Context-Aware Processing), By Component (Hardware, Software, Service), By Therapeutic Application (Oncology, Cardiology, Neurology, Respiratory, Other), By Region, By Competition
Global Artificial Intelligence In Precision Medicine Market has valued at USD 1.24 billion in 2022 and is anticipated to project impressive growth in the forecast period with a CAGR of 21.13% through 2028. In the ever-evolving landscape of healthcare, a powerful convergence is taking place between artificial intelligence (AI) and precision medicine. This groundbreaking synergy has the potential to transform the way medical treatments are developed, delivered, and personalized. The Global Artificial Intelligence in Precision Medicine Market is at the forefront of this paradigm shift, offering a glimpse into the future of healthcare innovation. Precision medicine, characterized by tailoring medical treatments and interventions to the individual characteristics of each patient, has gained considerable traction in recent years. This approach acknowledges the inherent diversity among patients, taking into account factors such as genetics, environment, and lifestyle. Meanwhile, AI technologies like machine learning and deep learning have demonstrated remarkable capabilities in analyzing vast amounts of data and extracting actionable insights. The amalgamation of these two domains holds immense promise for optimizing diagnosis, treatment selection, and patient outcomes.
Traditional one-size-fits-all medical approaches are gradually making way for personalized treatments. Patients and healthcare providers alike are recognizing the potential of AI to unlock the intricacies of individual health profiles, enabling tailored therapies. The decreasing cost of genomic sequencing has led to an explosion of genetic data. AI algorithms can swiftly sift through this information, identifying genetic markers associated with diseases, and paving the way for targeted interventions. The digitization of healthcare records and the proliferation of wearable devices have generated an unprecedented volume of patient data. AI can aggregate, analyse, and integrate these diverse data sources, yielding comprehensive insights that were previously unattainable. AI is revolutionizing the drug discovery process by predicting potential drug candidates, simulating drug interactions, and expediting preclinical testing. This not only reduces costs but also accelerates the delivery of innovative therapies to market.
Key Market Drivers
Rising Prevalence of Chronic Diseases is Driving the Global Artificial Intelligence In Precision Medicine Market
Chronic diseases, often referred to as non-communicable diseases (NCDs), encompass a wide range of health conditions such as cardiovascular diseases, diabetes, cancer, and respiratory illnesses. They are characterized by their prolonged duration, slow progression, and the requirement for ongoing medical attention and management. According to the World Health Organization (WHO), chronic diseases are responsible for almost 71% of all global deaths, with a staggering 85% of these deaths occurring in low- and middle-income countries. The socioeconomic impact of chronic diseases is profound, straining healthcare systems, reducing workforce productivity, and diminishing the quality of life for individuals and their families. Artificial Intelligence, specifically machine learning and deep learning techniques, has proven to be a transformative force in the healthcare industry. AI has the ability to process and analyze massive datasets, recognize complex patterns, and generate predictive models. When applied to precision medicine, AI can mine intricate relationships between genetic makeup, disease susceptibility, and treatment outcomes, leading to more accurate diagnoses and personalized therapeutic interventions. One of the significant applications of AI in precision medicine is in genomics research. AI algorithms can swiftly analyze a patient's genetic information and identify specific mutations or biomarkers associated with certain diseases. This information aids clinicians in making informed decisions about treatment strategies, enabling them to select medications that are more likely to be effective and minimize adverse effects. AI-powered tools are also revolutionizing medical imaging analysis. These tools can rapidly interpret images such as X-rays, MRIs, and CT scans, aiding in the early detection and diagnosis of various conditions like cancer, heart disease, and neurodegenerative disorders. Additionally, AI-driven predictive models can forecast disease progression, allowing physicians to intervene proactively and tailor treatment plans accordingly. The convergence of AI and precision medicine has resulted in a rapidly expanding market. According to market research reports, the Global Artificial Intelligence in Precision Medicine Market is projected to experience substantial growth over the coming years. Factors such as increased funding for research and development, growing partnerships between AI and healthcare companies, and the escalating demand for personalized treatments are driving this trend.
As technology continues to advance, the applications of AI in precision medicine will likely expand further. Integration of electronic health records, wearable devices, and real-time monitoring will provide a continuous stream of data for AI algorithms to analyze, enabling timely interventions and adjustments to treatment plans. Moreover, AI can aid in the discovery of novel drug targets and the development of innovative therapeutic interventions, ushering in a new era of precision medicine.
The Surge of Drug Discovery and Development Fuels Growth in Global Artificial Intelligence in Precision Medicine
In The field of drug discovery and development has always been a complex and time-consuming process. Researchers spend years identifying potential drug candidates, testing them for safety and efficacy, and then going through a lengthy regulatory approval process before they can finally reach patients. However, recent advancements in technology, particularly in the field of artificial intelligence (AI), are revolutionizing the way drugs are discovered and developed. This is particularly evident in the rising global market for AI in precision medicine. Precision medicine, also known as personalized medicine, is an innovative approach to healthcare that takes into account individual variability in genes, environment, and lifestyle for each person. By tailoring medical treatment and interventions to the unique characteristics of each patient, precision medicine aims to achieve better outcomes, reduce adverse effects, and ultimately improve patient care. Artificial intelligence has found a significant role in driving the precision medicine market. AI algorithms can analyze vast amounts of patient data, including genetic information, medical history, and lifestyle factors, to identify potential drug targets and predict how patients will respond to different treatments. This accelerates the drug discovery process, making it faster and more efficient.
One area where AI is making a considerable impact is in identifying potential drug candidates. Traditional methods of drug discovery often involve screening large libraries of chemical compounds, which can be time-consuming and expensive. AI algorithms, on the other hand, can quickly analyze vast amounts of data to identify potential drug targets and predict which compounds are likely to have a therapeutic effect. Additionally, AI is also being used to predict how patients will respond to different treatments. By analyzing patient data, AI algorithms can identify biomarkers that can help predict which patients are more likely to respond to a specific treatment, allowing for more targeted and personalized interventions.
One major driver of this growth is the increasing amount of data available for analysis. Advances in genomic sequencing technology have led to an explosion of genetic data, providing researchers with valuable insights into the underlying causes of diseases. AI algorithms can sift through this data to identify potential drug targets and predict patient responses.In addition, collaborations between pharmaceutical companies and technology firms are further propelling the growth of the AI in precision medicine market. These partnerships are enabling the development of innovative AI-driven tools and platforms that can accelerate drug discovery and development processes.
Key Market Challenges
Data Quality and Accessibility Poses a Significant Obstacle To Market Expansion
One of the primary challenges facing the AI-driven precision medicine market is the need for high-quality, diverse, and comprehensive healthcare data. AI algorithms rely heavily on large datasets to make accurate predictions and recommendations. However, healthcare data is often fragmented across various sources, including electronic health records, genomic data, wearable devices, and more. Integrating these disparate data sources while ensuring their accuracy and security remains a formidable challenge.
Data Privacy and Security
As AI applications in precision medicine require access to sensitive patient data, concerns about data privacy and security have come to the forefront. Balancing the benefits of AI-driven insights with patient confidentiality and data protection regulations is a significant hurdle. Striking the right balance between data sharing for research purposes and maintaining patient trust is crucial for the sustainable growth of the market.
Lack of Standardization
Incorporating AI into precision medicine involves the integration of complex data from multiple sources and the development of algorithms for analysis. The lack of standardized data formats and interoperability standards across healthcare systems and institutions poses a substantial barrier to seamless data sharing and collaboration. Efforts to establish common data standards are essential to facilitate the exchange of information and foster innovation.
Algorithm Bias and Interpretability
AI algorithms can inadvertently perpetuate biases present in training data, leading to disparities in healthcare outcomes. In precision medicine, biased algorithms could result in inaccurate diagnoses or treatments, particularly for underrepresented populations. Additionally, the 'black box' nature of some AI models poses challenges in understanding how decisions are reached, limiting their clinical acceptance. Striving for transparent and interpretable AI models is crucial for building trust among healthcare providers and patients.
Clinical Validation and Regulation
For AI-driven precision medicine solutions to gain widespread acceptance, they must undergo rigorous clinical validation to demonstrate their safety, efficacy, and reliability. Achieving regulatory approval for AI-based medical products is a complex process that requires navigating evolving guidelines and demonstrating real-world impact. Balancing innovation with patient safety remains a significant hurdle in bringing AI-enabled precision medicine technologies to market.
Integration into Clinical Workflow
Implementing AI solutions into the existing clinical workflow can be challenging. Healthcare professionals are already inundated with information, and integrating new technologies seamlessly without disrupting established processes is crucial. Providing user-friendly interfaces, ensuring minimal disruption, and demonstrating tangible benefits are essential to encourage adoption.
Cost and Resource Constraints
While the potential long-term benefits of AI in precision medicine are substantial, the initial investment required for technology implementation and training can be significant. Many healthcare institutions, especially in resource-constrained environments, might find it challenging to allocate funds for AI initiatives. Demonstrating the economic value and return on investment is crucial to overcoming these cost-related barriers.
Key Market Trends
Technological Advancements
Traditionally, medical treatments and interventions have followed a one-size-fits-all approach, often resulting in suboptimal outcomes due to individual variations in genetic makeup, lifestyle, and environmental factors. Precision medicine, on the other hand, embraces the uniqueness of each patient by tailoring medical decisions and interventions based on their specific characteristics. This approach has been made possible by advances in genomics, molecular biology, and personalized diagnostics. The complexity of analyzing vast amounts of patient data, including genetic information, medical histories, and lifestyle factors, requires tools that can sift through this data efficiently and extract meaningful insights. This is where artificial intelligence steps in, offering the computational power and algorithmic intelligence needed to make sense of the intricate web of patient information. AI in precision medicine involves the utilization of machine learning algorithms and deep learning techniques to identify patterns, correlations, and associations within large datasets. These patterns could relate to disease risk, treatment response, drug interactions, and more. The more data AI algorithms are exposed to, the better they become at identifying subtle connections that might elude human analysis.
The digitalization of healthcare records, along with the explosion of wearable devices and medical sensors, has led to an unprecedented volume of patient data. AI algorithms thrive on data, and this wealth of information enables them to make more accurate predictions and recommendations. The field of genomics has seen remarkable progress in deciphering the human genome and understanding the genetic basis of diseases. AI can aid in interpreting this vast genetic information and linking it to clinical outcomes. AI-driven simulations and virtual drug screening can expedite drug discovery and development, allowing for the creation of targeted therapies that are aligned with a patient's unique genetic profile. AI technologies can accelerate the analysis of medical data, leading to quicker diagnoses, optimized treatment plans, and shorter hospital stays. This not only improves patient outcomes but also reduces healthcare costs.
Segmental Insights
Technology Insights
Based on the Technology, the Deep Learning segment emerged as the dominant player in the global market for Artificial Intelligence In Precision Medicine in 2022. This can be attributed to the fact that precision medicine aims to tailor medical treatment and interventions to individual characteristics, allowing for more effective and personalized care. Deep Learning, a subset of machine learning, has proven to be exceptionally well-suited for solving complex problems in this field. Precision medicine involves analyzing a vast amount of heterogeneous data, including genomics, proteomics, medical images, electronic health records, and more. Deep Learning models, particularly neural networks, excel at learning intricate patterns and representations from such diverse and high-dimensional data types. One of the key strengths of Deep Learning is its ability to automatically extract relevant features from raw data. In precision medicine, where meaningful features might not be explicitly defined, Deep Learning models can identify subtle relationships and features that contribute to disease diagnosis, prognosis, and treatment. Many diseases have intricated underlying mechanisms that operate at various levels of complexity. Deep Learning's hierarchical architecture, with multiple layers of interconnected neurons, can capture these intricate patterns and relationships, making it well-suited for modeling complex disease processes.
Component Insights
The software segment is projected to experience rapid growth during the forecast period. Precision medicine relies heavily on analyzing vast amounts of patient data, including genomic, clinical, and lifestyle information. AI algorithms are capable of processing and extracting meaningful insights from these complex datasets. Software applications enable the development and deployment of these algorithms, allowing healthcare professionals to analyze patient data at a scale and complexity that would be impossible manually. AI algorithms, such as machine learning and deep learning models, are central to making sense of precision medicine data. These algorithms require large amounts of labeled data for training, fine-tuning, and validation. Software platforms provide the infrastructure for researchers and data scientists to design, develop, and train these AI models effectively.
Regional Insights
North America emerged as the dominant player in the global Artificial Intelligence In Precision Medicine market in 2022, holding the largest market share in terms of value. North America boasts advanced healthcare infrastructure, including well-established electronic health record (EHR) systems, which provide a wealth of patient data that can be used to train and validate AI algorithms for precision medicine. Access to high-quality data is crucial for developing accurate AI models. The region has witnessed substantial investments and funding for AI startups and companies working in the field of precision medicine. Venture capital firms and investors are drawn to the potential of combining AI with healthcare, driving innovation and growth in the market. North America, particularly the United States, has a robust ecosystem for research and innovation in both AI and medicine. Leading research universities, medical institutions, and technology companies in the region have been at the forefront of developing AI technologies for precision medicine applications. North America has a tradition of collaboration between the healthcare and technology sectors. This collaboration has facilitated the integration of AI solutions into medical practice. Partnerships between hospitals, research institutions, and tech companies have accelerated the development and adoption of AI-powered precision medicine tools.
Key Market Players
Glanbia Plc
BioXcel Therapeutics, Inc.
Sanofi S.A.
NVIDIA Corp.
Alphabet Inc. (Google Inc.)
IBM Technology corporation
Microsoft Corporation
Intel Corp.
AstraZeneca plc
GE HealthCare
Enlitic, Inc.
Report Scope:
In this report, the Global Artificial Intelligence In Precision Medicine Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:
Company Profiles: Detailed analysis of the major companies present in the Global Artificial Intelligence In Precision Medicine Market.
Available Customizations:
Global Artificial Intelligence In Precision Medicine market report with the given market data, Tech Sci Research offers customizations according to a company's specific needs. The following customization options are available for the report:
Company Information
Traditional one-size-fits-all medical approaches are gradually making way for personalized treatments. Patients and healthcare providers alike are recognizing the potential of AI to unlock the intricacies of individual health profiles, enabling tailored therapies. The decreasing cost of genomic sequencing has led to an explosion of genetic data. AI algorithms can swiftly sift through this information, identifying genetic markers associated with diseases, and paving the way for targeted interventions. The digitization of healthcare records and the proliferation of wearable devices have generated an unprecedented volume of patient data. AI can aggregate, analyse, and integrate these diverse data sources, yielding comprehensive insights that were previously unattainable. AI is revolutionizing the drug discovery process by predicting potential drug candidates, simulating drug interactions, and expediting preclinical testing. This not only reduces costs but also accelerates the delivery of innovative therapies to market.
Key Market Drivers
Rising Prevalence of Chronic Diseases is Driving the Global Artificial Intelligence In Precision Medicine Market
Chronic diseases, often referred to as non-communicable diseases (NCDs), encompass a wide range of health conditions such as cardiovascular diseases, diabetes, cancer, and respiratory illnesses. They are characterized by their prolonged duration, slow progression, and the requirement for ongoing medical attention and management. According to the World Health Organization (WHO), chronic diseases are responsible for almost 71% of all global deaths, with a staggering 85% of these deaths occurring in low- and middle-income countries. The socioeconomic impact of chronic diseases is profound, straining healthcare systems, reducing workforce productivity, and diminishing the quality of life for individuals and their families. Artificial Intelligence, specifically machine learning and deep learning techniques, has proven to be a transformative force in the healthcare industry. AI has the ability to process and analyze massive datasets, recognize complex patterns, and generate predictive models. When applied to precision medicine, AI can mine intricate relationships between genetic makeup, disease susceptibility, and treatment outcomes, leading to more accurate diagnoses and personalized therapeutic interventions. One of the significant applications of AI in precision medicine is in genomics research. AI algorithms can swiftly analyze a patient's genetic information and identify specific mutations or biomarkers associated with certain diseases. This information aids clinicians in making informed decisions about treatment strategies, enabling them to select medications that are more likely to be effective and minimize adverse effects. AI-powered tools are also revolutionizing medical imaging analysis. These tools can rapidly interpret images such as X-rays, MRIs, and CT scans, aiding in the early detection and diagnosis of various conditions like cancer, heart disease, and neurodegenerative disorders. Additionally, AI-driven predictive models can forecast disease progression, allowing physicians to intervene proactively and tailor treatment plans accordingly. The convergence of AI and precision medicine has resulted in a rapidly expanding market. According to market research reports, the Global Artificial Intelligence in Precision Medicine Market is projected to experience substantial growth over the coming years. Factors such as increased funding for research and development, growing partnerships between AI and healthcare companies, and the escalating demand for personalized treatments are driving this trend.
As technology continues to advance, the applications of AI in precision medicine will likely expand further. Integration of electronic health records, wearable devices, and real-time monitoring will provide a continuous stream of data for AI algorithms to analyze, enabling timely interventions and adjustments to treatment plans. Moreover, AI can aid in the discovery of novel drug targets and the development of innovative therapeutic interventions, ushering in a new era of precision medicine.
The Surge of Drug Discovery and Development Fuels Growth in Global Artificial Intelligence in Precision Medicine
In The field of drug discovery and development has always been a complex and time-consuming process. Researchers spend years identifying potential drug candidates, testing them for safety and efficacy, and then going through a lengthy regulatory approval process before they can finally reach patients. However, recent advancements in technology, particularly in the field of artificial intelligence (AI), are revolutionizing the way drugs are discovered and developed. This is particularly evident in the rising global market for AI in precision medicine. Precision medicine, also known as personalized medicine, is an innovative approach to healthcare that takes into account individual variability in genes, environment, and lifestyle for each person. By tailoring medical treatment and interventions to the unique characteristics of each patient, precision medicine aims to achieve better outcomes, reduce adverse effects, and ultimately improve patient care. Artificial intelligence has found a significant role in driving the precision medicine market. AI algorithms can analyze vast amounts of patient data, including genetic information, medical history, and lifestyle factors, to identify potential drug targets and predict how patients will respond to different treatments. This accelerates the drug discovery process, making it faster and more efficient.
One area where AI is making a considerable impact is in identifying potential drug candidates. Traditional methods of drug discovery often involve screening large libraries of chemical compounds, which can be time-consuming and expensive. AI algorithms, on the other hand, can quickly analyze vast amounts of data to identify potential drug targets and predict which compounds are likely to have a therapeutic effect. Additionally, AI is also being used to predict how patients will respond to different treatments. By analyzing patient data, AI algorithms can identify biomarkers that can help predict which patients are more likely to respond to a specific treatment, allowing for more targeted and personalized interventions.
One major driver of this growth is the increasing amount of data available for analysis. Advances in genomic sequencing technology have led to an explosion of genetic data, providing researchers with valuable insights into the underlying causes of diseases. AI algorithms can sift through this data to identify potential drug targets and predict patient responses.In addition, collaborations between pharmaceutical companies and technology firms are further propelling the growth of the AI in precision medicine market. These partnerships are enabling the development of innovative AI-driven tools and platforms that can accelerate drug discovery and development processes.
Key Market Challenges
Data Quality and Accessibility Poses a Significant Obstacle To Market Expansion
One of the primary challenges facing the AI-driven precision medicine market is the need for high-quality, diverse, and comprehensive healthcare data. AI algorithms rely heavily on large datasets to make accurate predictions and recommendations. However, healthcare data is often fragmented across various sources, including electronic health records, genomic data, wearable devices, and more. Integrating these disparate data sources while ensuring their accuracy and security remains a formidable challenge.
Data Privacy and Security
As AI applications in precision medicine require access to sensitive patient data, concerns about data privacy and security have come to the forefront. Balancing the benefits of AI-driven insights with patient confidentiality and data protection regulations is a significant hurdle. Striking the right balance between data sharing for research purposes and maintaining patient trust is crucial for the sustainable growth of the market.
Lack of Standardization
Incorporating AI into precision medicine involves the integration of complex data from multiple sources and the development of algorithms for analysis. The lack of standardized data formats and interoperability standards across healthcare systems and institutions poses a substantial barrier to seamless data sharing and collaboration. Efforts to establish common data standards are essential to facilitate the exchange of information and foster innovation.
Algorithm Bias and Interpretability
AI algorithms can inadvertently perpetuate biases present in training data, leading to disparities in healthcare outcomes. In precision medicine, biased algorithms could result in inaccurate diagnoses or treatments, particularly for underrepresented populations. Additionally, the 'black box' nature of some AI models poses challenges in understanding how decisions are reached, limiting their clinical acceptance. Striving for transparent and interpretable AI models is crucial for building trust among healthcare providers and patients.
Clinical Validation and Regulation
For AI-driven precision medicine solutions to gain widespread acceptance, they must undergo rigorous clinical validation to demonstrate their safety, efficacy, and reliability. Achieving regulatory approval for AI-based medical products is a complex process that requires navigating evolving guidelines and demonstrating real-world impact. Balancing innovation with patient safety remains a significant hurdle in bringing AI-enabled precision medicine technologies to market.
Integration into Clinical Workflow
Implementing AI solutions into the existing clinical workflow can be challenging. Healthcare professionals are already inundated with information, and integrating new technologies seamlessly without disrupting established processes is crucial. Providing user-friendly interfaces, ensuring minimal disruption, and demonstrating tangible benefits are essential to encourage adoption.
Cost and Resource Constraints
While the potential long-term benefits of AI in precision medicine are substantial, the initial investment required for technology implementation and training can be significant. Many healthcare institutions, especially in resource-constrained environments, might find it challenging to allocate funds for AI initiatives. Demonstrating the economic value and return on investment is crucial to overcoming these cost-related barriers.
Key Market Trends
Technological Advancements
Traditionally, medical treatments and interventions have followed a one-size-fits-all approach, often resulting in suboptimal outcomes due to individual variations in genetic makeup, lifestyle, and environmental factors. Precision medicine, on the other hand, embraces the uniqueness of each patient by tailoring medical decisions and interventions based on their specific characteristics. This approach has been made possible by advances in genomics, molecular biology, and personalized diagnostics. The complexity of analyzing vast amounts of patient data, including genetic information, medical histories, and lifestyle factors, requires tools that can sift through this data efficiently and extract meaningful insights. This is where artificial intelligence steps in, offering the computational power and algorithmic intelligence needed to make sense of the intricate web of patient information. AI in precision medicine involves the utilization of machine learning algorithms and deep learning techniques to identify patterns, correlations, and associations within large datasets. These patterns could relate to disease risk, treatment response, drug interactions, and more. The more data AI algorithms are exposed to, the better they become at identifying subtle connections that might elude human analysis.
The digitalization of healthcare records, along with the explosion of wearable devices and medical sensors, has led to an unprecedented volume of patient data. AI algorithms thrive on data, and this wealth of information enables them to make more accurate predictions and recommendations. The field of genomics has seen remarkable progress in deciphering the human genome and understanding the genetic basis of diseases. AI can aid in interpreting this vast genetic information and linking it to clinical outcomes. AI-driven simulations and virtual drug screening can expedite drug discovery and development, allowing for the creation of targeted therapies that are aligned with a patient's unique genetic profile. AI technologies can accelerate the analysis of medical data, leading to quicker diagnoses, optimized treatment plans, and shorter hospital stays. This not only improves patient outcomes but also reduces healthcare costs.
Segmental Insights
Technology Insights
Based on the Technology, the Deep Learning segment emerged as the dominant player in the global market for Artificial Intelligence In Precision Medicine in 2022. This can be attributed to the fact that precision medicine aims to tailor medical treatment and interventions to individual characteristics, allowing for more effective and personalized care. Deep Learning, a subset of machine learning, has proven to be exceptionally well-suited for solving complex problems in this field. Precision medicine involves analyzing a vast amount of heterogeneous data, including genomics, proteomics, medical images, electronic health records, and more. Deep Learning models, particularly neural networks, excel at learning intricate patterns and representations from such diverse and high-dimensional data types. One of the key strengths of Deep Learning is its ability to automatically extract relevant features from raw data. In precision medicine, where meaningful features might not be explicitly defined, Deep Learning models can identify subtle relationships and features that contribute to disease diagnosis, prognosis, and treatment. Many diseases have intricated underlying mechanisms that operate at various levels of complexity. Deep Learning's hierarchical architecture, with multiple layers of interconnected neurons, can capture these intricate patterns and relationships, making it well-suited for modeling complex disease processes.
Component Insights
The software segment is projected to experience rapid growth during the forecast period. Precision medicine relies heavily on analyzing vast amounts of patient data, including genomic, clinical, and lifestyle information. AI algorithms are capable of processing and extracting meaningful insights from these complex datasets. Software applications enable the development and deployment of these algorithms, allowing healthcare professionals to analyze patient data at a scale and complexity that would be impossible manually. AI algorithms, such as machine learning and deep learning models, are central to making sense of precision medicine data. These algorithms require large amounts of labeled data for training, fine-tuning, and validation. Software platforms provide the infrastructure for researchers and data scientists to design, develop, and train these AI models effectively.
Regional Insights
North America emerged as the dominant player in the global Artificial Intelligence In Precision Medicine market in 2022, holding the largest market share in terms of value. North America boasts advanced healthcare infrastructure, including well-established electronic health record (EHR) systems, which provide a wealth of patient data that can be used to train and validate AI algorithms for precision medicine. Access to high-quality data is crucial for developing accurate AI models. The region has witnessed substantial investments and funding for AI startups and companies working in the field of precision medicine. Venture capital firms and investors are drawn to the potential of combining AI with healthcare, driving innovation and growth in the market. North America, particularly the United States, has a robust ecosystem for research and innovation in both AI and medicine. Leading research universities, medical institutions, and technology companies in the region have been at the forefront of developing AI technologies for precision medicine applications. North America has a tradition of collaboration between the healthcare and technology sectors. This collaboration has facilitated the integration of AI solutions into medical practice. Partnerships between hospitals, research institutions, and tech companies have accelerated the development and adoption of AI-powered precision medicine tools.
Key Market Players
Glanbia Plc
BioXcel Therapeutics, Inc.
Sanofi S.A.
NVIDIA Corp.
Alphabet Inc. (Google Inc.)
IBM Technology corporation
Microsoft Corporation
Intel Corp.
AstraZeneca plc
GE HealthCare
Enlitic, Inc.
Report Scope:
In this report, the Global Artificial Intelligence In Precision Medicine Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:
- Artificial Intelligence In Precision Medicine Market, By Technology:
- Deep Learning
- Querying Method
- Natural Language Processing
- Artificial Intelligence In Precision Medicine Market, By Component :
- Hardware
- Software
- Service
- Artificial Intelligence In Precision Medicine Market, By Therapeutic Application :
- Oncology
- Cardiology
- Neurology
- Respiratory
- Other
- Artificial Intelligence In Precision Medicine Market, By Region:
- North America
- United States
- Canada
- Mexico
- Europe
- France
- United Kingdom
- Italy
- Germany
- Spain
- Asia-Pacific
- China
- India
- Japan
- Australia
- South Korea
- South America
- Brazil
- Argentina
- Colombia
- Middle East & Africa
- South Africa
- Saudi Arabia
- UAE
Company Profiles: Detailed analysis of the major companies present in the Global Artificial Intelligence In Precision Medicine Market.
Available Customizations:
Global Artificial Intelligence In Precision Medicine market report with the given market data, Tech Sci Research offers customizations according to a company's specific needs. The following customization options are available for the report:
Company Information
- Detailed analysis and profiling of additional market players (up to five).
1. PRODUCT OVERVIEW
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. VOICE OF CUSTOMER
5. GLOBAL ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET OUTLOOK
5.1. Market Size & Forecast
5.1.1. By Value
5.2. Market Share & Forecast
5.2.1. By Technology (Software Solutions, Hardware, Services)
5.2.2. By Cancer Type (Breast Cancer, Lung Cancer, Prostate Cancer, Colorectal Cancer, Brain Tumor, Others)
5.2.3. By End-User (Hospital, Surgical Centers and Medical Institutes, Others)
5.2.4. By Region
5.2.5. By Company (2022)
5.3. Market Map
6. NORTH AMERICA ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET OUTLOOK
6.1. Market Size & Forecast
6.1.1. By Value
6.2. Market Share & Forecast
6.2.1. By Technology
6.2.2. By Cancer Type
6.2.3. By End-User
6.2.4. By Form
6.2.5. By Distribution Channel
6.2.6. By Country
6.3. North America: Country Analysis
6.3.1. United States Artificial Intelligence In Precision Medicine Market Outlook
6.3.1.1. Market Size & Forecast
6.3.1.1.1. By Value
6.3.1.2. Market Share & Forecast
6.3.1.2.1. By Technology
6.3.1.2.2. By Cancer Type
6.3.1.2.3. By End-User
6.3.2. Canada Artificial Intelligence In Precision Medicine Market Outlook
6.3.2.1. Market Size & Forecast
6.3.2.1.1. By Value
6.3.2.2. Market Share & Forecast
6.3.2.2.1. By Technology
6.3.2.2.2. By Cancer Type
6.3.2.2.3. By End-User
6.3.3. Mexico Artificial Intelligence In Precision Medicine Market Outlook
6.3.3.1. Market Size & Forecast
6.3.3.1.1. By Value
6.3.3.2. Market Share & Forecast
6.3.3.2.1. By Technology
6.3.3.2.2. By Cancer Type
6.3.3.2.3. By End-User
7. EUROPE ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET OUTLOOK
7.1. Market Size & Forecast
7.1.1. By Value
7.2. Market Share & Forecast
7.2.1. By Technology
7.2.2. By Cancer Type
7.2.3. By End-User
7.3. Europe: Country Analysis
7.3.1. Germany Artificial Intelligence In Precision Medicine Market Outlook
7.3.1.1. Market Size & Forecast
7.3.1.1.1. By Value
7.3.1.2. Market Share & Forecast
7.3.1.2.1. By Technology
7.3.1.2.2. By Cancer Type
7.3.1.2.3. By End-User
7.3.2. United Kingdom Artificial Intelligence In Precision Medicine Market Outlook
7.3.2.1. Market Size & Forecast
7.3.2.1.1. By Value
7.3.2.2. Market Share & Forecast
7.3.2.2.1. By Technology
7.3.2.2.2. By Cancer Type
7.3.2.2.3. By End-User
7.3.3. Italy Artificial Intelligence In Precision Medicine Market Outlook
7.3.3.1. Market Size & Forecast
7.3.3.1.1. By Value
7.3.3.2. Market Share & Forecasty
7.3.3.2.1. By Technology
7.3.3.2.2. By Cancer Type
7.3.3.2.3. By End-User
7.3.4. France Artificial Intelligence In Precision Medicine Market Outlook
7.3.4.1. Market Size & Forecast
7.3.4.1.1. By Value
7.3.4.2. Market Share & Forecast
7.3.4.2.1. By Technology
7.3.4.2.2. By Cancer Type
7.3.4.2.3. By End-User
7.3.5. Spain Artificial Intelligence In Precision Medicine Market Outlook
7.3.5.1. Market Size & Forecast
7.3.5.1.1. By Value
7.3.5.2. Market Share & Forecast
7.3.5.2.1. By Technology
7.3.5.2.2. By Cancer Type
7.3.5.2.3. By End-User
8. ASIA-PACIFIC ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET OUTLOOK
8.1. Market Size & Forecast
8.1.1. By Value
8.2. Market Share & Forecast
8.2.1. By Technology
8.2.2. By Cancer Type
8.2.3. By End-User
8.3. Asia-Pacific: Country Analysis
8.3.1. China Artificial Intelligence In Precision Medicine Market Outlook
8.3.1.1. Market Size & Forecast
8.3.1.1.1. By Value
8.3.1.2. Market Share & Forecast
8.3.1.2.1. By Technology
8.3.1.2.2. By Cancer Type
8.3.1.2.3. By End-User
8.3.2. India Artificial Intelligence In Precision Medicine Market Outlook
8.3.2.1. Market Size & Forecast
8.3.2.1.1. By Value
8.3.2.2. Market Share & Forecast
8.3.2.2.1. By Technology
8.3.2.2.2. By Cancer Type
8.3.2.2.3. By End-User
8.3.3. Japan Artificial Intelligence In Precision Medicine Market Outlook
8.3.3.1. Market Size & Forecast
8.3.3.1.1. By Value
8.3.3.2. Market Share & Forecast
8.3.3.2.1. By Technology
8.3.3.2.2. By Cancer Type
8.3.3.2.3. By End-User
8.3.4. South Korea Artificial Intelligence In Precision Medicine Market Outlook
8.3.4.1. Market Size & Forecast
8.3.4.1.1. By Value
8.3.4.2. Market Share & Forecast
8.3.4.2.1. By Technology
8.3.4.2.2. By Cancer Type
8.3.4.2.3. By End-User
8.3.5. Australia Artificial Intelligence In Precision Medicine Market Outlook
8.3.5.1. Market Size & Forecast
8.3.5.1.1. By Value
8.3.5.2. Market Share & Forecast
8.3.5.2.1. By Technology
8.3.5.2.2. By Cancer Type
8.3.5.2.3. By End-User
9. SOUTH AMERICA ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET OUTLOOK
9.1. Market Size & Forecast
9.1.1. By Value
9.2. Market Share & Forecast
9.2.1. By Technology
9.2.2. By Cancer Type
9.2.3. By End-User
9.3. South America: Country Analysis
9.3.1. Brazil Artificial Intelligence In Precision Medicine Market Outlook
9.3.1.1. Market Size & Forecast
9.3.1.1.1. By Value
9.3.1.2. Market Share & Forecast
9.3.1.2.1. By Technology
9.3.1.2.2. By Cancer Type
9.3.1.2.3. By End-User
9.3.2. Argentina Artificial Intelligence In Precision Medicine Market Outlook
9.3.2.1. Market Size & Forecast
9.3.2.1.1. By Value
9.3.2.2. Market Share & Forecast
9.3.2.2.1. By Technology
9.3.2.2.2. By Cancer Type
9.3.2.2.3. By End-User
9.3.3. Colombia Artificial Intelligence In Precision Medicine Market Outlook
9.3.3.1. Market Size & Forecast
9.3.3.1.1. By Value
9.3.3.2. Market Share & Forecast
9.3.3.2.1. By Technology
9.3.3.2.2. By Cancer Type
9.3.3.2.3. By End-User
10. MIDDLE EAST AND AFRICA ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET OUTLOOK
10.1. Market Size & Forecast
10.1.1. By Value
10.2. Market Share & Forecast
10.2.1. By Technology
10.2.2. By Cancer Type
10.2.3. By End-User
10.3. MEA: Country Analysis
10.3.1. South Africa Artificial Intelligence In Precision Medicine Market Outlook
10.3.1.1. Market Size & Forecast
10.3.1.1.1. By Value
10.3.1.2. Market Share & Forecast
10.3.1.2.1. By Technology
10.3.1.2.2. By Cancer Type
10.3.1.2.3. By End-User
10.3.2. Saudi Arabia Artificial Intelligence In Precision Medicine Market Outlook
10.3.2.1. Market Size & Forecast
10.3.2.1.1. By Value
10.3.2.2. Market Share & Forecast
10.3.2.2.1. By Technology
10.3.2.2.2. By Cancer Type
10.3.2.2.3. By End-User
10.3.3. UAE Artificial Intelligence In Precision Medicine Market Outlook
10.3.3.1. Market Size & Forecast
10.3.3.1.1. By Value
10.3.3.2. Market Share & Forecast
10.3.3.2.1. By Technology
10.3.3.2.2. By Cancer Type
10.3.3.2.3. By End-User
11. MARKET DYNAMICS
12. MARKET TRENDS & DEVELOPMENTS
13. GLOBAL ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET: SWOT ANALYSIS
14. COMPETITIVE LANDSCAPE
14.1. Business Overview
14.2. Cancer Type Offerings
14.3. Recent Developments
14.4. Key Personnel
14.5. SWOT Analysis
14.5.1. Medial EarlySign
14.5.2. Cancer Center.ai
14.5.3. Microsoft Corporation
14.5.4. Flatiron Health
14.5.5. Path AI
14.5.6. Therapixel
14.5.7. Tempus Labs, Inc.
14.5.8. Paige AI, Inc.
14.5.9. Kheiron Medical Technologies Limited
14.5.10. SkinVision
15. STRATEGIC RECOMMENDATIONS
16. ABOUT US & DISCLAIMER
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. VOICE OF CUSTOMER
5. GLOBAL ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET OUTLOOK
5.1. Market Size & Forecast
5.1.1. By Value
5.2. Market Share & Forecast
5.2.1. By Technology (Software Solutions, Hardware, Services)
5.2.2. By Cancer Type (Breast Cancer, Lung Cancer, Prostate Cancer, Colorectal Cancer, Brain Tumor, Others)
5.2.3. By End-User (Hospital, Surgical Centers and Medical Institutes, Others)
5.2.4. By Region
5.2.5. By Company (2022)
5.3. Market Map
6. NORTH AMERICA ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET OUTLOOK
6.1. Market Size & Forecast
6.1.1. By Value
6.2. Market Share & Forecast
6.2.1. By Technology
6.2.2. By Cancer Type
6.2.3. By End-User
6.2.4. By Form
6.2.5. By Distribution Channel
6.2.6. By Country
6.3. North America: Country Analysis
6.3.1. United States Artificial Intelligence In Precision Medicine Market Outlook
6.3.1.1. Market Size & Forecast
6.3.1.1.1. By Value
6.3.1.2. Market Share & Forecast
6.3.1.2.1. By Technology
6.3.1.2.2. By Cancer Type
6.3.1.2.3. By End-User
6.3.2. Canada Artificial Intelligence In Precision Medicine Market Outlook
6.3.2.1. Market Size & Forecast
6.3.2.1.1. By Value
6.3.2.2. Market Share & Forecast
6.3.2.2.1. By Technology
6.3.2.2.2. By Cancer Type
6.3.2.2.3. By End-User
6.3.3. Mexico Artificial Intelligence In Precision Medicine Market Outlook
6.3.3.1. Market Size & Forecast
6.3.3.1.1. By Value
6.3.3.2. Market Share & Forecast
6.3.3.2.1. By Technology
6.3.3.2.2. By Cancer Type
6.3.3.2.3. By End-User
7. EUROPE ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET OUTLOOK
7.1. Market Size & Forecast
7.1.1. By Value
7.2. Market Share & Forecast
7.2.1. By Technology
7.2.2. By Cancer Type
7.2.3. By End-User
7.3. Europe: Country Analysis
7.3.1. Germany Artificial Intelligence In Precision Medicine Market Outlook
7.3.1.1. Market Size & Forecast
7.3.1.1.1. By Value
7.3.1.2. Market Share & Forecast
7.3.1.2.1. By Technology
7.3.1.2.2. By Cancer Type
7.3.1.2.3. By End-User
7.3.2. United Kingdom Artificial Intelligence In Precision Medicine Market Outlook
7.3.2.1. Market Size & Forecast
7.3.2.1.1. By Value
7.3.2.2. Market Share & Forecast
7.3.2.2.1. By Technology
7.3.2.2.2. By Cancer Type
7.3.2.2.3. By End-User
7.3.3. Italy Artificial Intelligence In Precision Medicine Market Outlook
7.3.3.1. Market Size & Forecast
7.3.3.1.1. By Value
7.3.3.2. Market Share & Forecasty
7.3.3.2.1. By Technology
7.3.3.2.2. By Cancer Type
7.3.3.2.3. By End-User
7.3.4. France Artificial Intelligence In Precision Medicine Market Outlook
7.3.4.1. Market Size & Forecast
7.3.4.1.1. By Value
7.3.4.2. Market Share & Forecast
7.3.4.2.1. By Technology
7.3.4.2.2. By Cancer Type
7.3.4.2.3. By End-User
7.3.5. Spain Artificial Intelligence In Precision Medicine Market Outlook
7.3.5.1. Market Size & Forecast
7.3.5.1.1. By Value
7.3.5.2. Market Share & Forecast
7.3.5.2.1. By Technology
7.3.5.2.2. By Cancer Type
7.3.5.2.3. By End-User
8. ASIA-PACIFIC ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET OUTLOOK
8.1. Market Size & Forecast
8.1.1. By Value
8.2. Market Share & Forecast
8.2.1. By Technology
8.2.2. By Cancer Type
8.2.3. By End-User
8.3. Asia-Pacific: Country Analysis
8.3.1. China Artificial Intelligence In Precision Medicine Market Outlook
8.3.1.1. Market Size & Forecast
8.3.1.1.1. By Value
8.3.1.2. Market Share & Forecast
8.3.1.2.1. By Technology
8.3.1.2.2. By Cancer Type
8.3.1.2.3. By End-User
8.3.2. India Artificial Intelligence In Precision Medicine Market Outlook
8.3.2.1. Market Size & Forecast
8.3.2.1.1. By Value
8.3.2.2. Market Share & Forecast
8.3.2.2.1. By Technology
8.3.2.2.2. By Cancer Type
8.3.2.2.3. By End-User
8.3.3. Japan Artificial Intelligence In Precision Medicine Market Outlook
8.3.3.1. Market Size & Forecast
8.3.3.1.1. By Value
8.3.3.2. Market Share & Forecast
8.3.3.2.1. By Technology
8.3.3.2.2. By Cancer Type
8.3.3.2.3. By End-User
8.3.4. South Korea Artificial Intelligence In Precision Medicine Market Outlook
8.3.4.1. Market Size & Forecast
8.3.4.1.1. By Value
8.3.4.2. Market Share & Forecast
8.3.4.2.1. By Technology
8.3.4.2.2. By Cancer Type
8.3.4.2.3. By End-User
8.3.5. Australia Artificial Intelligence In Precision Medicine Market Outlook
8.3.5.1. Market Size & Forecast
8.3.5.1.1. By Value
8.3.5.2. Market Share & Forecast
8.3.5.2.1. By Technology
8.3.5.2.2. By Cancer Type
8.3.5.2.3. By End-User
9. SOUTH AMERICA ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET OUTLOOK
9.1. Market Size & Forecast
9.1.1. By Value
9.2. Market Share & Forecast
9.2.1. By Technology
9.2.2. By Cancer Type
9.2.3. By End-User
9.3. South America: Country Analysis
9.3.1. Brazil Artificial Intelligence In Precision Medicine Market Outlook
9.3.1.1. Market Size & Forecast
9.3.1.1.1. By Value
9.3.1.2. Market Share & Forecast
9.3.1.2.1. By Technology
9.3.1.2.2. By Cancer Type
9.3.1.2.3. By End-User
9.3.2. Argentina Artificial Intelligence In Precision Medicine Market Outlook
9.3.2.1. Market Size & Forecast
9.3.2.1.1. By Value
9.3.2.2. Market Share & Forecast
9.3.2.2.1. By Technology
9.3.2.2.2. By Cancer Type
9.3.2.2.3. By End-User
9.3.3. Colombia Artificial Intelligence In Precision Medicine Market Outlook
9.3.3.1. Market Size & Forecast
9.3.3.1.1. By Value
9.3.3.2. Market Share & Forecast
9.3.3.2.1. By Technology
9.3.3.2.2. By Cancer Type
9.3.3.2.3. By End-User
10. MIDDLE EAST AND AFRICA ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET OUTLOOK
10.1. Market Size & Forecast
10.1.1. By Value
10.2. Market Share & Forecast
10.2.1. By Technology
10.2.2. By Cancer Type
10.2.3. By End-User
10.3. MEA: Country Analysis
10.3.1. South Africa Artificial Intelligence In Precision Medicine Market Outlook
10.3.1.1. Market Size & Forecast
10.3.1.1.1. By Value
10.3.1.2. Market Share & Forecast
10.3.1.2.1. By Technology
10.3.1.2.2. By Cancer Type
10.3.1.2.3. By End-User
10.3.2. Saudi Arabia Artificial Intelligence In Precision Medicine Market Outlook
10.3.2.1. Market Size & Forecast
10.3.2.1.1. By Value
10.3.2.2. Market Share & Forecast
10.3.2.2.1. By Technology
10.3.2.2.2. By Cancer Type
10.3.2.2.3. By End-User
10.3.3. UAE Artificial Intelligence In Precision Medicine Market Outlook
10.3.3.1. Market Size & Forecast
10.3.3.1.1. By Value
10.3.3.2. Market Share & Forecast
10.3.3.2.1. By Technology
10.3.3.2.2. By Cancer Type
10.3.3.2.3. By End-User
11. MARKET DYNAMICS
12. MARKET TRENDS & DEVELOPMENTS
13. GLOBAL ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET: SWOT ANALYSIS
14. COMPETITIVE LANDSCAPE
14.1. Business Overview
14.2. Cancer Type Offerings
14.3. Recent Developments
14.4. Key Personnel
14.5. SWOT Analysis
14.5.1. Medial EarlySign
14.5.2. Cancer Center.ai
14.5.3. Microsoft Corporation
14.5.4. Flatiron Health
14.5.5. Path AI
14.5.6. Therapixel
14.5.7. Tempus Labs, Inc.
14.5.8. Paige AI, Inc.
14.5.9. Kheiron Medical Technologies Limited
14.5.10. SkinVision
15. STRATEGIC RECOMMENDATIONS
16. ABOUT US & DISCLAIMER
